Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), EXACT Sciences Corporation (NASDAQ:EXAS), Endocyte (NASDAQ:ECYT), Arena Pharmaceuticals (NASDAQ:ARNA)

Gilead Sciences Inc. (NASDAQ:GILD) announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the “Notes”) submitted for conversion on or after February 1 2014 entirely in cash. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -4.01% in last session and finished the day at $68.55. Traded volume was 29.25million shares in the last session and the average volume of the stock remained 12.71million shares. The beta of the stock remained 0.55. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.

Exact Sciences Corp. (NASDAQ:EXAS) announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences Corporation (NASDAQ:EXAS) has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard®, the company’s stool-based DNA (sDNA), non-invasive colorectal cancer screening test. EXACT Sciences Corporation (NASDAQ:EXAS) dropped -6.47 percent to $12.86 Friday on volume of 9.32million shares. The intra-day range of the stock was $12.52 to $14.60. EXACT Sciences Corporation (NASDAQ:EXAS) has a market capitalization of $915.65million.

Endocyte, Inc. (NASDAQ:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share. The gross proceeds to Endocyte, Inc. (NASDAQ:ECYT) from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Endocyte, Inc. (NASDAQ:ECYT), will be approximately $94.5 million. Endocyte, Inc. (NASDAQ:ECYT)’s stock on Mar 28, 2014 reported a decrease of -4.81% to the closing price of $21.96. Its fifty two weeks range is $8.18-$33.70. The total market capitalization recorded $796.43million. The overall volume in the last trading session was 7.26million shares. In its share capital, ECYT has 36.15million outstanding shares.

Belviq, the new weight-loss drug from Arena Pharmaceuticals Inc. (NASDAQ:ARNA), has begun testing in a Phase 2 clinical trial to help smokers kick the habit. San Diego’s Arena said in a Thursday regulatory filing that it is conducting the clinical trial along with its marketing partner, the Japanese drugmaker Eisai. On Friday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -3.17% to close the day at $6.10. Company return on investment (ROI) is -13.90% and its monthly performance is recorded as -9.90%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is 2.01%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone